Clozapine Therapy Monitoring and Management

Initial Assessment and Baseline Testing

Before starting clozapine, baseline white blood cell (WBC) count must be at least 3,500/mm³ with no evidence of myeloproliferative disorder or history of agranulocytosis, and avoid concurrent medications that may lower blood cell counts, according to the American Academy of Child and Adolescent Psychiatry 1, 2
Obtain baseline measurements of body mass index (BMI), waist circumference, fasting glucose, HbA1c, and liver function tests, as recommended by Praxis Medical Insights 3

Optimal therapeutic plasma levels are between 350-550 ng/mL, as suggested by Praxis Medical Insights 4, 5

Weekly blood cell counts are required for the first 6 months of treatment, every 2 weeks for the next 6 months, and monthly after 12 months of continuous therapy, with continued monitoring for 4 weeks after medication discontinuation, as recommended by the American Academy of Child and Adolescent Psychiatry and Praxis Medical Insights 1, 2, 3

If WBC drops below 2,000/mm³ or absolute neutrophil count (ANC) below 1,000/mm³, stop medication immediately and monitor for infection with daily blood counts, as recommended by Praxis Medical Insights and the American Academy of Child and Adolescent Psychiatry 1, 3
If WBC is between 3,000-3,500/mm³ or drops by 3,000/mm³ over 1-3 weeks, repeat blood count and monitor biweekly until WBC >3,500/mm³, as suggested by the American Academy of Child and Adolescent Psychiatry 1, 2

Seizure risk is dose-related, increasing especially with rapid dose increases, and occurs in approximately 3% of patients, according to the American Academy of Child and Adolescent Psychiatry 1, 2
Regular follow-up of fasting glucose, BMI, waist circumference, blood pressure, and lipid panel is necessary, as recommended by Praxis Medical Insights 3
Monitor for weight gain, which can be significant and is a common side effect, as noted by the American Academy of Child and Adolescent Psychiatry 1, 2